TCRX vs. AMLX
TCRX (TScan Therapeutics, Inc.) and AMLX (Amylyx Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, TCRX returned -29.80%/yr vs -19.37%/yr for AMLX. At a 0.19 correlation, their price movements are largely independent.
Performance
TCRX vs. AMLX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TCRX achieves a -2.80% return, which is significantly lower than AMLX's 9.27% return.
TCRX
- 1D
- -0.82%
- 1M
- -20.33%
- YTD
- -2.80%
- 6M
- -4.71%
- 1Y
- -44.46%
- 3Y*
- -29.80%
- 5Y*
- —
- 10Y*
- —
AMLX
- 1D
- -0.68%
- 1M
- -19.81%
- YTD
- 9.27%
- 6M
- -7.11%
- 1Y
- 157.81%
- 3Y*
- -19.37%
- 5Y*
- —
- 10Y*
- —
TCRX vs. AMLX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
TCRX TScan Therapeutics, Inc. | -2.80% | -67.11% | -47.86% | 276.13% | -66.16% |
AMLX Amylyx Pharmaceuticals, Inc. | 9.27% | 219.58% | -74.32% | -60.16% | 104.48% |
Correlation
The correlation between TCRX and AMLX is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.30 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since Jan 10, 2022 | 0.19 |
The correlation between TCRX and AMLX shifts across timeframes, from 0.19 (all time) to 0.30 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
TCRX:
$126.28M
AMLX:
$1.46B
TCRX:
-$0.96
AMLX:
-$1.55
TCRX:
1.30
AMLX:
5.34
TCRX:
$8.15M
AMLX:
$0.00
TCRX:
$6.66M
AMLX:
-$20.10M
TCRX:
-$129.32M
AMLX:
-$150.30M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TCRX vs. AMLX — Risk / Return Rank
TCRX
AMLX
TCRX vs. AMLX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for TScan Therapeutics, Inc. (TCRX) and Amylyx Pharmaceuticals, Inc. (AMLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| TCRX | AMLX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.89 | ||
| Sortino ratioReturn per unit of downside risk | -3.55 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.36 | -0.40 |
| Calmar ratioReturn relative to maximum drawdown | -0.69 | 5.19 | -5.88 |
| Martin ratioReturn relative to average drawdown | -1.01 | 11.73 | -12.73 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| TCRX | AMLX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.52 | 2.37 | -2.89 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.39 | -0.08 | -0.32 |
Drawdowns
TCRX vs. AMLX - Drawdown Comparison
The maximum TCRX drawdown since its inception was -93.36%, roughly equal to the maximum AMLX drawdown of -96.04%. Use the drawdown chart below to compare losses from any high point for TCRX and AMLX.
Loading charts...
Drawdown Indicators
| TCRX | AMLX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.36% | -96.04% | +2.68% |
Max Drawdown (1Y)Largest decline over 1 year | -64.46% | -30.61% | -33.85% |
Max Drawdown (3Y)Largest decline over 3 years | -90.58% | -93.83% | +3.25% |
Current DrawdownCurrent decline from peak | -92.79% | -67.75% | -25.04% |
Average DrawdownAverage peak-to-trough decline | -71.82% | -59.36% | -12.46% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 44.25% | 13.52% | +30.73% |
Volatility
TCRX vs. AMLX - Volatility Comparison
TScan Therapeutics, Inc. (TCRX) has a higher volatility of 17.58% compared to Amylyx Pharmaceuticals, Inc. (AMLX) at 14.15%. This indicates that TCRX's price experiences larger fluctuations and is considered to be riskier than AMLX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TCRX | AMLX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.58% | 14.15% | +3.43% |
Volatility (6M)Calculated over the trailing 6-month period | 50.67% | 41.86% | +8.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 87.56% | 66.96% | +20.60% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 98.20% | 91.49% | +6.71% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 98.20% | 91.49% | +6.71% |
Dividends
TCRX vs. AMLX - Dividend Comparison
Neither TCRX nor AMLX has paid dividends to shareholders.
Financials
TCRX vs. AMLX - Financials Comparison
This section allows you to compare key financial metrics between TScan Therapeutics, Inc. and Amylyx Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
TCRX and AMLX have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TCRX has higher volatility (17.58%) compared to AMLX (14.15%). In terms of maximum drawdown, TCRX dropped -93.36% vs AMLX's -96.04%.
AMLX currently has the higher Sharpe Ratio (2.37 vs -0.52), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TCRX and AMLX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer